A detailed history of Rhumbline Advisers transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 47,203 shares of TCRX stock, worth $190,228. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,203
Previous 46,867 0.72%
Holding current value
$190,228
Previous $274,000 14.23%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.97 - $7.49 $1,669 - $2,516
336 Added 0.72%
47,203 $235,000
Q2 2024

Aug 01, 2024

BUY
$5.85 - $9.51 $274,171 - $445,705
46,867 New
46,867 $274,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $76.3M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.